



ALTERNATIVE TO PTO/SB/08a/s (06-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Application Number	09/615,285
				Filing Date	July 12, 2000
				First Named Inventor	Daniel E. H. AFAR
				Art Unit	1642
				Examiner Name	G. NICKOL
				Attorney Docket Number	511582000820

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code*-Number*-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GN	1.	AFAR D.E. et al. (2001). "Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia." <i>Cancer Res.</i> 61(4):1686-1692.	
	2.	HESSELS D. et al. (2004). "Applicability of biomarkers in the early diagnosis of prostate cancer." <i>Expert Rev. Mol. Diagn.</i> 4(4):513-526.	
	3.	LIN B. et al. (1999). "Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2." <i>Cancer Res.</i> 59(17):4180-4184.	
	4.	PAOLONI-GIACOBINO A. et al. (2001). "Corrigenda." <i>Genomics</i> 77(1-2):114. (Correction to PAOLONI-GIACOBINO A. et al. (1997). "Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA, and SRCR Domains and Maps to 21q22.3." <i>Genomics</i> , 44(3):309-320.)	
	5.	VAARALA M.H. et al. (2001). "The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease." <i>Int. J. Cancer</i> 94(5):705-710.	
	6.	WILSON S. et al. (2004). "The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells." <i>Biochem. J.</i> Nov. 10, 2004 [Epub ahead of print], located at < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15537383 > last visited on December 1, 2004, 2 pages.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Gary Nickol</i>	Date Considered	2/09/05
pa-939250			